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and oropharynx area, we developed two orthotopic tumour 
mouse models in these two sites. Both models are biolumi-
nescent in order to follow up the tumour growth by imag-
ing and are induced by cell injection without the need to 
intervene surgically. These models were utilized for immu-
notherapies with genetic or plant-derived therapeutic vac-
cines. In particular, the head/neck orthotopic model appears 
to be very promising for studies combining chemo-radio-
immune therapy that seems to be very effective in patients.
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Abbreviations
16E7SH  Shuffled HPV-16 E7
APC  Antigen-Presenting Cells
CIN  Cervical intraepithelial neoplasia
CP  Capsid protein
CTL  Cytotoxic T-lymphocytes
DTH  Delayed-type hypersensitivity
EP  Electroporation
HNC  Head and neck cancer
HPV  Human papillomavirus
HR-HPV  High-risk HPV
Hsp70  Heat shock protein 70
IgG  Immunoglobulins
Ii  Invariant chain
LicKM  Circularly permutated lichenase
MHC  Major histocompatibility complex
N9  Nonoxynol-9
NK  Natural killer
OSCC  Oral squamous cell carcinoma
PVX  Potato virus X
RIPs  Ribosome-inactivating proteins
SAP  Saporin
Abstract Under the optimistic assumption of high-pro-
phylactic HPV vaccine coverage, a significant reduction of 
cancer incidence can only be expected after decades. Thus, 
immune therapeutic strategies are needed for persistently 
infected individuals who do not benefit from the prophy-
lactic vaccines. However, the therapeutic strategies induc-
ing immunity to the E6 and/or E7 oncoprotein of HPV16 
are more effective for curing HPV-expressing tumours 
in animal models than for treating human cancers. New 
strategies/technologies have been developed to improve 
these therapeutic vaccines. Our studies focussed on pre-
paring therapeutic vaccines with low-cost technologies by 
DNA preparation fused to either plant-virus or plant-toxin 
genes, such as saporin, and by plant-produced antigens. 
In particular, plant-derived antigens possess an intrinsic 
adjuvant activity that makes these preparations especially 
attractive for future development. Additionally, discrepancy 
in vaccine effectiveness between animals and humans may 
be due to non-orthotopic localization of animal models. 
Orthotopic transplantation leads to tumours giving a more 
accurate representation of the parent tumour. Since HPV 
can cause cancer in two main localizations, anogenital 
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TAA  Tumour-associated antigens
TAP  Transporter associated with antigen processing
TLR  Toll-like receptors
Treg  Regulatory T-lymphocyte
VLP  Virus-like particles
Introduction
All cervical cancers and precancerous lesions (CIN III) are 
caused by HPV infection. Since the early findings in the 
1970s of HPV in cervical cancer by zur Hausen’s group, 
HPV has been linked to other anogenital cancers including 
vulvar, penile, and anal neoplasia. Recently, high-risk HPV 
(HR-HPV) infection has been detected in head and neck 
cancers (HNCs), with high frequency in oropharynx and 
tonsils, unveiling another aetiological factor in addition to 
tobacco and alcohol [1].
Screenings for pre-malignant lesions of the cervix and 
more recently HPV tests have led to a decrease in cervical 
cancer in developed countries with high costs for follow-up 
visits. Unfortunately, vaccination and screening programs 
for cervical cancer in developing countries are very diffi-
cult, and for this reason, cervical cancer represents a major 
cause of death in women. Furthermore, there is yet no 
valid screening to identify early HPV-positive (or negative) 
HNCs. HPV-negative HNCs are declining, which may be 
related to less tobacco consumption, whereas HPV-positive 
oropharyngeal cancer is increasing with an expected higher 
rate than cervical cancer in the 2020s in the USA [2].
Although the natural history of HPV-associated oral 
cancer is still not well known, similarities exist with cer-
vical cancer, such as the number of cancers increases with 
increasing number of sexual partners, and therefore, some 
paradigms of HPV function can be adapted for HNC. From 
this perspective, plausibly preventive vaccines against HPV 
infection will also work in preventing oropharyngeal can-
cers. A population-based study in Costa Rica showed that 
HPV prevalence in the oropharynx of vaccinated women 
four years after follow-up was much lower among the vac-
cine arm compared with the control arm, suggesting that 
the vaccine strongly protects against oral HPV infection, 
and therefore may prevent also HPV-associated oropharyn-
geal cancers [3].
Currently available preventive vaccines against HPV are 
based on virus-like particles (VLPs) prepared by recom-
binant expression and assembly of the major capsid pro-
tein L1. Merck’s yeast-made Gardasil and GSK’s insect-
cell-made Cervarix are VLP-based vaccines both highly 
effective/powerful but not cost-effective; consequently, 
their use is hampered in developing countries where HPV 
accounts for ~85 % of both annual cervical cancer cases 
(~500,000 cases worldwide) and deaths from cervical 
cancer (~300,000 worldwide) [4]. The costs and cost-effec-
tiveness of these vaccines will remain a problem even if 
the second-generation vaccines will include wider cover-
age like combination of more types of HPV L1 vaccines 
(Gardasil 9-valent), or chimeric L1/fragment L2 vaccines, 
or L2-based vaccines [5]. Neither of these vaccines, Gar-
dasil or Cervarix, have any effect on established infections; 
thus, million people already infected need a therapeutic 
intervention. No specific/effective pharmacological treat-
ments exist; thus, immunotherapy can be a valid option, 
particularly because the HPV lesion/cancer possesses 
strong tumour-associated antigens (TAA) represented by 
the major oncoproteins E6/E7 always expressed and neces-
sary to maintain the transformation status. Together with a 
broad spectrum of preventive HPV vaccinations, also treat-
ments of persistent infections, precancerous lesions, and 
early-stage tumour by immunotherapy could lessen the bur-
den of HPV disease.
Vaccine-mediated immune strategies can be directed 
towards at least two different steps of the HPV oncogenic 
process: primary infections by prophylactic vaccines and 
established infections by immunotherapy targeted to early 
proteins, in particular E6–E7 oncoproteins. Treatments by 
immunotherapy could have an immediate impact on HPV-
associated cancer, whereas prophylactic vaccines will take 
decades to lead to death reduction due to this pathology. 
Therapeutic vaccines are aimed to eradicate or to reduce 
already infected cells. Indeed, E6 and E7 proteins are 
always associated with tumour cells and are not expressed 
on the cell surface, making an antibody-based immune 
response unlikely to eliminate already infected cells. In 
HPV-infected/transformed keratinocytes, the constitutive 
expression of E6 and E7 results in their peptides being pre-
sented on the surface of cells by MHC class I molecules. 
These infected cells can be now recognized by cytotoxic 
T-lymphocytes (CTL) that play a pivotal role in clearance 
of virus-infected cells.
The primary CTL response is activated by the presenta-
tion of foreign antigen on the surface of antigen-presenting 
cells (APC) within MHC class I molecules. Since HPV 
does not infect primarily APC to allow usual class I pro-
cessing, HPV antigens at some stage of infection or follow-
ing cell trauma are released from infected cells and APCs 
are able to process these exogenous protein to produce 
class I-linked peptides and prime CTLs. In addition, APCs 
present HPV antigens also within class II MHC molecule 
priming in particular CD4+ helper T cells. CD4+ T cells 
are essential for both a valid cellular and humoral immune 
response. The conditions of T-helper lymphocyte activation 
decide their phenotype resulting in two populations, Th1 
and Th2. The equilibrium between Th1 and Th2 is often 
altered in HPV infection with reduced Th1 and increased 
Th2 response associated with lesion progression [6]. On 
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the other hand, induction of specific CTLs and T-helper has 
been recognized in patients regressing from natural HPV 
infection [7]. Thus, similar immunological responses must 
be elicited by a therapeutic vaccine in order to eliminate 
HPV-infected/transformed cells.
Therefore, the basic principle of therapeutic vaccine is to 
stimulate cytotoxic T cells against the target infected cells 
together with an up-regulation of MHC Class I expression. 
Since the first human trials on late-stage cervical cancer, it 
was clear that by reason of the immunosuppressive environ-
ment generated by tumours in cases of advanced disease, 
an immunological anti-tumour effect could be effective 
only together with ordinary therapy. This immunosup-
pressive milieu (partially related to HPV action) involves: 
(1) the disruption of antigen processing and presenta-
tion machinery by altering the MHC class I and TAP 1–2 
expression [8]; (2) the recruitment of immunosuppressive 
T regulatory cells (Treg) to dampen effector T cell activity; 
and (3) the chemokine production altering T cell homoeo-
stasis and increasing the sensitivity of effector T cells to 
apoptosis [9]. Thus, a valid therapy in late stage of disease 
should not only induce cytotoxic activity, but also break the 
immunotolerance/immunoescape of the tumour. To achieve 
this result, we can benefit from the existence of known pre-
cursors to the tumour of cervix, anus, or vulva in which this 
immunosuppressive environment is less active. In alterna-
tive, we can modify the vaccine/immunotherapy schedule 
in order to attract effector cells to the site of action. Experi-
mental vaccines developed against E6–E7 oncogenes have 
shown some effectiveness in animal models and human tri-
als. However, given that most of the cervical disease bur-
den as well as cancer occurs in developing countries, the 
problem of costs and smaller size of the market will be 
once again an issue that should be settled by any licensed 
vaccines [10, 11]. In an attempt to produce a valid immu-
notherapy possibly at low cost against HPV-associated 
lesion/cancer, our studies have focused on the development 
of low-cost platforms, such as DNA and plant biotech-
nologies. To produce tailor-made and potentiated formu-
lations, plants will be utilized as bio-factories or “mines” 
of immune stimulators. More importantly, and regardless 
of the formulation type, clinical trials require pre-clinical 
assays and models to predict the treatment efficacy. In 
particular, pre-clinical models resembling human patholo-
gies are necessary. Our studies were therefore focussed on 
developing orthotopic models of HPV lesions/cancers.
DNA vaccines
DNA-based vaccines are increasingly considered to be a 
promising therapeutic approach against malignancies as 
they are safe, easy to produce at high purity, and provide 
stable expression of the encoded antigen [12]. This type 
of vaccine-based approach may also have adjuvant func-
tions, such as plasmid DNA harbouring unmethylated 
CpG motifs, which can be recognized by Toll-like recep-
tors (TLR)-9 stimulating innate immunity [13, 14]. DNA 
vaccination is producing non-live, non-replicating, non-
spreading antigens capable of inducing both CTL and Th 
immunity, as well as B cell immunity. In addition, multi-
ple DNA administrations are feasible without triggering an 
immune response against the DNA plasmid. This method 
may therefore be particularly useful in the context of thera-
peutic cancer vaccination, where repeated vaccinations are 
often required to boost effective T cell responses. Several 
pre-clinical and clinical DNA vaccine studies against HPV-
induced malignancies have been conducted, and clinical 
trials are described elsewhere [10, 11].
The association between antigens and proteins capa-
ble of inter- and intra-cellular transport has been shown to 
enhance the spread of antigens encoded by DNA vaccines. 
Our group has developed strategies aimed at enhancing 
antigen processing through the MHC class I or II pathways. 
Fusion genes consisting of HPV16 E7 oncogene fused to 
the genes for ubiquitin or the invariant chain (Ii) were pro-
duced, in order to increase the presentation of E7-derived 
peptides by MHC class I or II molecules, respectively. 
DNA vaccination of C57BL/6 mice was performed with 
these fusion genes, and the animals were subsequently 
challenged with E7-positive tumour cell lines express-
ing different levels of MHC class I molecules. A number 
of animals were protected from tumour challenging by the 
E7-Ii fusion gene [15].
A harmless version of the HPV16 E7 gene, the E7GGG 
mutant that was produced by introducing three amino acid 
substitutions at the binding site for pRb [16], was fused to 
the 3’ end of a capsid protein (CP) of a plant virus produc-
ing another DNA fusion vaccine [17]. Indeed, CPs, in par-
ticular those of the potato virus X (PVX), have been largely 
used as carrier proteins for a range of epitopes of animal 
pathogens [18]. Moreover, as they act as primary antigens 
in humans with the ability to aggregate in structures acti-
vating CD4+ T responses [19], CPs assume the role of 
pathogen-derived dominant antigens that could enhance 
the immunogenicity of poor/silent determinants [20]. The 
efficacy of different DNA constructs was assayed in a 
mouse model, the TC-1 cell line. TC-1 cells are derived 
from immortalized mouse cells expressing HPV16 E6/
E7 and Ras oncogenes and are able to produce tumours in 
syngeneic C57BL6 mice [21]. This model is widely used 
to assess the efficacy of therapeutic anti-HPV vaccines. In 
therapeutic vaccination experiments with pcDNA/E7GGG-
CP fusion constructs, a greater number of mice challenged 
with tumour-inducing E7-expressing TC-1 cells are pro-
tected (60 %) compared with pcDNA/E7GGG alone. This 
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difference indicates that engineering the intracellular path-
way for antigen presentation produces a valid therapeutic 
response, at least in mouse models [17].
HPV collaborates with molecules implicated in the 
immune surveillance process, depleting apoptosis and cre-
ating an immunosuppressive tumour environment associ-
ated with an ineffective immune response to the viral early 
antigens, E7 and E6 [11, 22]. Consequently, approaches 
were developed to boost the “strength” of vaccines against 
the targeted tumour antigens in order to utilize new genes/
proteins with immunomodulatory/stimulatory properties. 
An example of these vaccines fused to immunostimulant 
proteins that has reached phase I clinical trial in CIN 2/3 
patients is the DNA vaccine encoding a signal sequence 
for the endoplasmic reticulum linked to an attenuated form 
of HPV16 E7 gene fused to Hsp70 (Sig/E7detox/Hsp70). 
Results of this clinical trial demonstrated safety and tolera-
bility of the vaccine with histological regression in 3 out of 
9 patients treated with the highest dose. Although this his-
tological regression was not statistically significant, some 
HPV-specific T cell responses elicited in patients offer 
promising therapeutic perspective [23]. Indeed, same vac-
cine boosted with the recombinant vaccinia virus encoding 
HPV16/18 E6/E7 fusion protein TA-HPV with or without 
imiquimod is now utilized in another clinical trial started in 
2008 with expected results in 2016 [24]. Possible autoim-
mune responses induced by Hsp70 are one of constraints 
in using this kind of vaccines. However, human HSP70 
instead of mycobacterium tuberculosis HSP70 significantly 
decreases autoimmune disease risk [25]. Nevertheless, 
improvement in therapeutic HPV vaccines in clinical trials 
has to take into account any possible problem that may be 
amplified by combination strategies of different therapeutic 
modalities [26].
In seeking novel immunostimulatory sequences with 
less limitations to their clinical use (i.e. autoimmune dis-
ease), our group has created a new strategy using plant-
derived carriers, represented by “Ribosome inactivating 
proteins” (RIPs). RIPs are an inhibitor family of cellular 
protein synthesis, and they are found in different organs of 
many plant species where they have regulatory and defen-
sive roles [27]. They are N-glycosidases that remove spe-
cific adenine bases in 23S/25S/28S rRNA triggering pro-
tein synthesis arrest at the translocation step and inducing 
cell death. Due to its toxic activity, RIPs together with tar-
geting molecules (i.e. monoclonal antibodies) have shown 
great potential for their use as selective killing agents of 
tumour, immune or nerve cells in medicine. Unfortunately, 
these chimerical toxins did not turn out to be perfect clini-
cal tools as their clinical application was hampered by 
immunogenicity of the toxin moiety and by non-specific 
toxicity leading to vascular leak syndrome [28]. Regard-
less of cytotoxicity by protein synthesis arrest, other RIPs 
biological characteristics could contribute to the design of 
therapeutic anti-tumour vaccines. In particular, RIPs are 
characterized by: (1) a high antigenicity that could be help-
ful in boosting immune response against fused tumour/
viral antigens; (2) the ability to modulate non-specific and 
innate immune functions affecting NK, CD4+, and CD8+ 
T cells, and cytokine production; and (3) the induction 
of inflammation and apoptosis [29]. Saporins belong to a 
multigene family of single chain (type 1) RIPs, which are 
formed in various organs of Saponaria officinalis (soap-
wort). Saporins have been used to develop immunotoxins 
against cancer cells for their catalytic activity once pene-
trated in the cytoplasm. They are stable proteins resistant to 
derivation and conjugation processes. In addition, indepen-
dently of inhibiting translation, saporin has been shown to 
induce cell death via apoptosis in a variety of cellular mod-
els [29]. A fusion construct of a non-toxic saporin mutant 
(SAP-KQ) with HPV16 E7GGG gene was generated. This 
construct affected tumour growth of E7-expressing TC-1 
cells inducing E7-specific immunoglobulins (IgG), CTLs, 
and delayed-type hypersensitivity (DTH) [30]. In the con-
text of DNA-based vaccination, these data demonstrate that 
mutant plant genes are potentially capable of improving the 
poor immunogenicity of tumour-associated cancer antigens 
fostering the development of new cancer immunotherapy. 
In addition, our E7 vaccines were utilized in prime/boost 
schedule with recombinant fowl-pox virus showing some 
promising results in mice [31].
A further improvement in fusion DNA vaccines could 
be achieved by modifying administration routes as well as 
schedules of vaccination. The introduction of electropo-
ration (EP) represents a major advancement in DNA vac-
cination. EP consists of applying short electric pulses to 
the site of vaccination after intramuscular or intradermal 
plasmid DNA administration. EP increases plasmid uptake 
and generates a local inflammatory cell infiltrate, leading 
to a stronger immune response to the vaccine. In regards 
to the comparison of EP safety after DNA vaccination with 
that of DNA delivered without EP, there is no increased 
risk of toxicity nor integration of the plasmid DNA into 
the genome of the host cell. Indeed, a recent Phase I clini-
cal trial conducted by EP of E6/E7 HPV16 and 18 DNA 
vaccine ascertained its completely safe administration in 
humans [32]. For this reason, our E7-SAP vaccine will be 
used via EP in pre-clinical models.
Literature data, along with our results on different HPV 
DNA vaccines, support the use of DNA vaccines as valu-
able tools in therapeutic development of HPV vaccine. EP 
protocols or heterologous DNA prime and viral vector-based 
boosts could increase immunogenicity of HPV TAA. In 
addition, DNA vaccine efficiency in clinical setting will be 
further enhanced by combination with Treg depletion, which 
may be a valid tool in avoiding immune escape [33, 34].
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Plant‑derived vaccines
Originally, vaccines from plants were developed with 
the idea of edible vaccines [35, 36]. However, it became 
soon clear that this concept was not feasible because the 
administration of vaccines to humans requires standardiz-
ing doses, and establishing measures of quality control for 
purification and formulation [36]. The production of plant-
based vaccines against different pathogens has been devel-
oped over the last few decades in prophylactic and thera-
peutic settings and is reviewed elsewhere [37]. Recently, 
the first Food and Drug Administration qualified clinical 
study of a plant-derived vaccine on non-Hodgkin’s lym-
phoma has demonstrated that plant proteins are safe just 
like biologicals from other sources, when given as paren-
teral administration. Additionally, immune responses to the 
specific antigenic determinants were observed in 66 % of 
patients, and not towards xenogeneic plant antigens [38]. 
Therefore, plant-produced vaccines can be utilized in 
humans following standardized procedures. In this field, 
the production of plant-based vaccines against HPV was 
developed for producing VLP for prophylactic vaccines 
as well as E6/E7 antigens for immunotherapy. The major 
accomplishments in plant-produced VLP prove that HPV 
capsid protein L1 can self-assemble in transgenic plants 
[39, 40], and the derived VLP induces immune responses in 
rabbit models [41]. Initially, low yields of plant-produced 
VLPs were observed; however, recent attempts via agro-
infiltration-mediated transient expression or via transplas-
tomic (chloroplast) expression showed higher yields of 
HPV-16 L1 and VLPs [42].
Our research group was the first to investigate plant-
derived therapeutic vaccines based on the HPV-16 E7 
oncoprotein. A recombinant PVX vector successfully 
induced transient expression of the HPV16 E7 protein in 
Nicotiana benthamiana plants. Specific immune responses 
were induced in mice by tobacco plant extracts contain-
ing E7 protein. These immunological responses induced 
protection from tumour growth of E7-expressing C3 cell 
line coupled to strong cytotoxic T cell responses [43]. The 
immunological activity of plant-produced vaccine was 
hampered by the low level of E7 in the tobacco extracts but, 
by forcing E7 to the secretory pathway, it was possible to 
obtain an enhanced expression of the protein. This higher 
level of E7 within the tobacco extracts increased immuno-
logical responses and therapeutic vaccine effectiveness in 
the same mouse model [44]. It was clear from these experi-
ments that, in the presence of plant extract, E7 antigens are 
effective in eliciting CTL response in the absence of any 
adjuvant molecules.
The word adjuvant comes from “adjuvare”, the Latin 
term for to help. Traditionally, when developing adjuvants, 
the main aim was to boost humoral immune responses, and 
as a result, most of the commonly used adjuvants are effec-
tive in raising serum antibody titres, without significantly 
eliciting Th1 responses or CTLs. Thus, a therapeutic set-
ting in which strong CTL responses are elicited by adju-
vant activity of plant extracts is particularly useful. Moreo-
ver, other studies showed plant extract immunomodulatory 
activity in vitro on dendritic cells [45].
To address potential concerns on using oncoproteins in 
vaccines, our group engineered mutations that eliminated 
any interactions with cell cycle governing proteins, the 
already mentioned E7GGG mutant, in order to attain a safe 
version of the oncoprotein. With the aim of further enhanc-
ing the therapeutic efficacy of E7GGG antigen, we con-
structed a new vaccine by fusing E7 antigen to a lichenase 
(LicKM), the beta-1,3-1,4-glucanase of Clostridium ther-
mocellum and by producing it in tobacco plant using an 
innovative transient expression system, the pBID4 launch 
vector, which possesses the advantageous features of agro-
bacterial binary plasmids and those of plant viral vectors 
[46]. This plant-produced fusion E7GGG/LicKM antigen 
was evaluated as a possible therapeutic vaccine against 
HPV-induced tumours in TC-1 mouse model [47]. Data 
from induction of E7-specific IgG, DTH, and ELISPOT 
indicated that E7GGG/LicKM fusion proteins were highly 
immunogenic, capable of inducing both humoral and cell-
mediated immune responses, superior to those generated by 
immunization with E. coli-produced E7GGG. In addition, 
during the administration of vaccine preparations without 
the use of adjuvants, our group observed that only tobacco-
produced fusion proteins were able to prevent tumour 
growth. This observation indicates that LicKM fusion pro-
teins play a key role in activating both innate and adaptive 
antigen-specific immune responses.
The therapeutic capabilities of these fusion antigens 
were further explored by starting vaccinations when TC-1 
tumours were already palpable, and by assessing overall 
survival. The outcome of this study clearly demonstrated 
that this plant-produced LicKM-E7GGG fusion antigen is 
a valid therapeutic vaccine candidate by curing established 
experimental tumours in mice, as well as having a strik-
ing effect on the overall survival of treated animals [48]. 
Through metal-ion affinity chromatography and gel filtra-
tion, the production of this fusion protein with 99 % purity 
was scaled up to 100 mg/Kg biomass, which is an appropri-
ate quantity for industrial production [49]. Thus, the pos-
sible use of this fusion vaccine in clinical trials is expected.
Our group investigated also an alternative production 
technique of E7GGG protein by recombinant chloroplast of 
Chlamydomonas reinhardtii, a well-characterized unicel-
lular alga [50]. E7GGG was expressed to levels of 0.12 % 
of total soluble protein (TSP). Chlamydomonas rein-
hardtii E7 extracts or purified protein plus QuilA adjuvant 
was injected in C57BL/6 mice to produce immunological 
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responses. These preparations induced specific anti-E7 
IgGs and E7-specific T cell proliferation in mice as well 
as tumour protection after challenging with E7 expressing 
TC-1 tumour cell line. This was the first successful expres-
sion of a soluble E7 in plants. Moreover, the efficacy of 
the alga extracts in the absence of any adjuvant molecules 
demonstrated that even algae possess an immune-enhanc-
ing activity as shown for tobacco plants.
Other data about adjuvant activity of plant components 
come from a study on the synthetic shuffled HPV-16 E7 
(16E7SH) that has no transforming function [51]. This 
16E7SH was fused to the Zera® peptide, a self-assembly 
domain of the maize gamma-zein seed storage protein, 
which drives recombinant proteins into endoplasmic reticu-
lum. This fusion protein was effective in mice vaccination 
but, more interestingly, even a mixture of Zera and 16E7SH 
was able to induce enhanced immune responses, suggest-
ing an adjuvant activity for the Zera® component unrelated 
to the construct. Thus, we can state that different plant 
components have common immune-potentiating effects 
on therapeutic vaccines, which further consolidate the use 
of plant-based platforms in preparing vaccines. Currently, 
there are ongoing studies investigating and characterizing 
the presence of molecules with adjuvant activity bound to 
plant-produced E7 antigen aiming to validate and explain 
the underlying immune-enhancer effects of these vaccines. 
These analyses will achieve new insights of adjuvant mol-
ecules interacting with E7.
Future studies will focus on producing a fusion protein 
E7GGG/SAP not only in tobacco plants, but also in root 
cultures that are emerging as valid production tools [37]. 
Given the effectiveness of the E7GGG/SAP DNA vaccine 
in therapeutic setting, we reason that further developments 
of this vaccine will be a heterologous DNA prime/matched-
protein boost scheduling, in order to increase the efficacy. 
Plant-based production of therapeutic vaccines against 
HPV diseases shows great potential for the future as these 
vaccines can be produced at high yield via transient expres-
sion and possesses anti-tumour and immune-enhancing 
activity at least in animal models. The possibility to scale 
up the production of antigens makes this technology suit-
able for effective translation into clinic.
New orthotopic mouse models
Therapeutic programs for persistently infected individuals 
beyond the help of prophylactic vaccines are needed. The 
induction of specific immune responses to the non-struc-
tural oncoproteins of HPV can be achieved in humans and 
animals with appropriate immunotherapy. However, most 
of the developed therapeutic strategies are more effective 
for curing HPV transplantable tumours in animal models 
than for treating human HPV cancers. One of the possi-
ble causes of this discrepancy is represented by the non-
orthotopic localization of the experimental animal models. 
Indeed, most of well-studied animal models are based on 
subcutaneous/intramuscular challenging of C57BL/6 mice 
with HPV16 expressing tumour cells, such as the embry-
onic C3 line or the epithelial TC-1 line. These models 
were useful in evaluating the safety of therapeutic vaccines 
and in examining whether they can induce HPV-specific 
immune responses that can eradicate a transplanted tumour. 
However, these models are quite different because E6 and 
E7 genes are under the control of a retroviral promoter 
in TC-1 cell line, while the natural promoter controls the 
expression of HPV genes in C3 cell line. Thus, this differ-
ence could be relevant in estimating the effectiveness of 
therapeutic vaccines.
It has been observed that an orthotopic transplantation, 
i.e. a tumour transplantation into the same body site from 
which the primitive tumour derived, represents more accu-
rately the parental tumour. Since HPV can cause cancer in 
two main areas, anogenital and oropharynx area, and both 
sites appear susceptible to immunotherapy, we focussed 
our research on orthotopic mouse models of cancer in these 
two sites [52]. In order to follow up the tumour growth 
without surgical intervention, both models were engineered 
to be bioluminescent for imaging.
The genital orthotopic model was originally developed 
by Decrausaz et al. [53], and we have reproduced the same 
model with our TC-1* star cells that are more aggressive 
than the parental TC-1 cells, giving 100 % of tumour upon 
inoculation in the flank of mice [48]. Briefly, TC-1* cells 
were infected by luciferase-encoding lentiviral vector pro-
ducing bioluminescent cells for in vivo imaging of tumour 
growth (Fig. 1a). After in vitro passages, TC-1*-Luc cells 
were transplanted into the mouse vagina pre-treated with 
nonoxynol-9 (N9) in order to disrupt transiently the vagi-
nal epithelium favouring the trapping of injected cells 
and the development of luminescent vaginal tumours. An 
example of this orthotopic HPV-associated mouse genital 
tumour is presented in Fig. 1b. This model was not fur-
ther developed due to the arduous task of dealing with the 
experimental procedures, and in our hands, sometimes the 
tumour expands into the peritoneal area broadening the gap 
between the model and the human pathology. Moreover, 
TC-1 cells did not derive from the same anatomical area, 
and they did not represent a proper orthotopic transplanta-
tion. However, this model retains the immunological fea-
tures of naturally occurring HPV tumours [53].
The second model of orthotopic HPV-associated cancer 
is based on oral localization. To the best of our knowledge, 
this is the first mouse model of HPV-associated HNC. Our 
orthotopic mouse model for HPV-related oral tumours 
derived from the murine AT-84 cell line, stemming from a 
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spontaneous oral squamous cell carcinoma (OSCC) of C3H 
mice. This model represents more precisely the ancestral 
tumour probably due to the presence of the same microen-
vironment [54]. In particular, it resembles human cancer in 
histological features, frequent lung metastases, recurrences, 
and successful surgery/chemo/radiotherapy.
When considering all these aspects, this animal model 
is a valid tool for testing novel therapies. The newly devel-
oped AT-84 E7 model maintains all the properties of the 
parental cells with addition of HPV16 E7 oncoprotein 
expression. Once implanted, the stable expression of this 
oncogene is maintained, not only within the tumour, but 
also in distant metastases (Fig. 2a, b) [55]. This result fur-
ther supports the utility of this orthotopic mouse model for 
HPV-related human oral cancer, as E7 expression is always 
maintained in oral human cancer and metastases. Indeed, 
E7 protein expression levels are similar to those observed 
in naturally occurring HPV tumours. The low expression 
level of E7 in AT-84 E7 tumours compared with other 
non-orthotopic models (i.e. C3 and TC-1) may provide a 
more realistic picture of the natural condition of HPV-
related tumours. Indeed, the great difference between the 
high expression levels of E7 in C3 and TC-1 models and 
the low levels in human cancers is a plausible explanation 
why several immunotherapies proven efficacious in C3 and 
TC-1 models failed to be effective in humans. Thus, AT-84 
E7 cells may represent the best oral model to test the fea-
sibility of therapeutic vaccination. This model was further 
improved by making AT-84 E7 bioluminescent by Lenti-
Luc infection, allowing less invasive and more accurate 
follow-up [55].
Although this preliminary work regarding AT-84 E7 
model for immunotherapy was not designed to assess 
immunological responses, the results provided infor-
mation on the efficacy of heterologous prime-boost 
regimens compared with homologous prime-boost 
Fig. 1  Genital mouse model of HPV-associated cancer. TC-1* cells 
were infected with Lenti-Luc vector to generate TC-1*-Luc cells. a 
Different concentrations of TC-1*-Luc cells (triplicates) were plated 
in 96-well plates, and D-luciferin (final concentration of 0.15 mg/
ml) was added 15 min before monitoring. Bioluminescence was 
measured by imaging system and calculated as photons/s/cm2/sr. 
Each point is mean ± SD. b Diestrum synchronized eight-week-old 
female C57BL/6 mice were pre-treated with a spermicidal/detergent 
N9 (4 %), and after 6 h washed with phosphate-buffered saline before 
challenging with 5 × 104 TC-1*-Luc cells. Genital tumour growth 
was monitored at the indicated time interval post-challenge. Biolu-
minescence was measured 15 min after intraperitoneal injection of 
D-luciferin by imaging system and quantified as photons/s/cm2/sr in 
a colour scale
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regimens, as reported in previous studies [23, 56]. 
Mice were vaccinated with different plant-derived for-
mulations (DNA-based or plant-produced) to observe 
whether or not and to what extent anti-tumour activity 
was triggered in the AT-84 E7 model. These tailored 
formulations had already shown their ability to inhibit 
TC-1 tumour growth. Homologous or heterologous 
prime/boost regimens appeared to be less effective in 
AT-84 E7 than in TC-1 model, with strong effects on 
tumour burden and poor action on tumour onset [17]. 
In addition, AT-84 E7-Luc model not only permitted 
tumour mass measurement better than calliper, but also 
showed high capacity to detect cancer earlier. Indeed, 
a tumour mass was first evident on the eighth day 
post-transplantation when a palpable tumour is barely 
detectable.
However, several aspects need to be improved in order 
to have a completely reliable model. For instance, informa-
tion on the biological significance of the E7 expression in 
these tumours is lacking, but preliminary data indicate that 
the presence of E7 can improve cell growth rate. Neverthe-
less, our model holds a valid place in monitoring responses 
to immunotherapy, as it is orthotopic and derives from nat-
urally occurring OSCC.
In conclusion, we strongly believe that our oral HPV-
associated mouse tumour represents an innovative, real-
istic, and new pre-clinical model for HPV-related OSCC. 
Moreover, the possibility of applying chemo-radiotherapy 
Fig. 2  Head and neck mouse model of HPV-associated cancer: intra-
tumoural therapy. a The presence of bioluminescent metastases in 
explanted organs of mice carrying the AT-84 E7 Luc tumours. Bio-
luminescence was measured by imaging system after addition of 
D-luciferin. b Time-course of luciferase expression in AT-84 E7 Luc 
tumour and metastasis. Bioluminescence was calculated as photons/
sec/cm2/sr, and data are mean ± SD of 5 animals. c Representative 
intratumoural treatment. Treatment with indicated DNA vaccine prep-
arations was performed by a prime dose (100 µg) i.m. 3 days after 
AT-84 E7 Luc injection in the mouth pavement followed 6 days later 
by DNA vaccine inoculation (100 µg) within the tumour. Tumour 
growth was monitored at the indicated time intervals post-challenge. 
Bioluminescence was measured 15 min after intraperitoneal injection 
of D-luciferin by imaging system and quantified as photons/s/cm2/sr 
in a colour scale. pVax, empty vector; pVax E7SAP, fusion between 
HPV16 E7GGG and mutated Saporin; pVax E7GGG, HPV16 
E7GGG gene
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to this model together with easy surgical removal of tumour 
masses offers new perspectives to test current available 
patient therapy in a pre-clinical model. It is well known that 
the better prognosis of HPV-positive OSCC could allow 
less aggressive chemo-radiotherapy, and in this regard, our 
model will be very useful, and we are performing several 
protocols of combined therapy (chemo/radio and immu-
notherapy). Furthermore, the localization of this tumour 
permits easy access to intratumoural therapy. Preliminary 
interesting results of E7GGG/SAP DNA intratumoural 
injection are shown in Fig. 2c, indicating the validity of this 
model in exploring new promising ways of treatment.
Concluding remarks
Our studies are aimed at the development of low-cost tech-
nologies, such as DNA vaccines as well as plant-produced 
vaccines, and have proven that these immunotherapies are 
ready for clinical use. The oral pre-clinical model of HPV-
associated cancer will have a pivotal role in designing new 
combined intervention in HPV-positive OSCC. Ongoing 
works is aimed at the development of new DNA/plant-
derived vaccines against other HPV targets like the E5 
oncogene of HR-HPV [57] in association with new emerg-
ing biological therapies [58].
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